<DOC>
	<DOCNO>NCT00501462</DOCNO>
	<brief_summary>This open-label study measure blood level different part drug call GKS189075 . People participate study receive single dose 250mg GSK189075 mouth . About 20 people mild moderate decrease renal ( kidney ) function ask participate study . They compare 20 healthy participant close age body size . People participate study stay clinical research unit begin 2 day receive single dose GSK189075 remain approximately one day receive study drug . During study urine collect begin day receive study drug day , prior leave clinical research unit . Blood sample also collect various time begin immediately 24 hour receive study drug .</brief_summary>
	<brief_title>A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>A female eligible enter participate study Nonchildbearing potential negative pregnancy test screen Childbearing potential , negative serum pregnancy test screening , lactating , agree adequate contraception . Satisfactory medical evaluation base upon medical history , medication history , physical examination , clinical laboratory data obtain Screening visit . Body weight &gt; 50 kg . BMI within range 19 40 kg/m2 . Signed date write informed consent prior participation protocolspecific procedure , include screening procedure . The subject able understand comply protocol requirement , instruction , protocolstated restriction . Additional Inclusion Criteria Subjects Renal Insufficiency : Subjects renal insufficiency must consider investigator clinically stable . Subjects must continue meet criterion stable renal function upon checkin clinic History regular alcohol consumption average &gt; 7 drink per week woman &gt; 14 drink per week men within 6 month Screening . One drink equivalent 12 g alcohol = 5 ounce ( oz ; 150 ml ) wine 12 oz ( 360 ml ) beer 1.5 oz ( 45 ml ) 80 proof distil spirit . A positive drug alcohol test Screening Checkin . Smokers allow enrol study ; however , smoke interferes collection/recording ongoing study procedure allow . Smoking status record CRF . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose study medication current study . The subject donate 450mL blood within 56 day period prior first schedule administration GSK189075 . Known suspect gastroparesis , gastric surgery within 6 month prior screen , gastrointestinal condition would likely interfere absorption GSK189075 . Subjects clinical laboratory value outside rage specify protocols Any subject either document cirrhosis history consistent diagnosis cirrhosis . Urinary tract bladder infection within 4 week first schedule administration study drug . Positive hepatitis B surface antigen , HIV Screening . If negative test result document within last 2 month , necessary repeat test . Subjects positive result hepatitis C antibody may eligible normal liver enzyme history hepatitis approve GSK medical monitor . Any history myocardial infarction , cardiac syncope . A history clinically significant cardiac arrhythmia ( individual case discuss GSK Medical Monitor ) . A history unstable angina past 6 month . Cardiac conduction abnormality denote range specify protocol Systolic blood pressure &lt; 80 mmHg &gt; 180 mmHg Diastolic blood pressure &lt; 60 mmHg &gt; 100 mmHg Use prescription nonprescription drug ( include high dose vitamin , herbal dietary supplement [ include St. John 's Wort ] ) within 7 day prior administration first dose study medication , unless opinion investigator Sponsor medication interfere study procedure compromise subject safety . Some allowable exception find Permitted Medications section ( Section 9.1 ) . Additional Exclusion Criteria Subjects Renal Insufficiency Patients new drug regimen ( define start new drug change dosage regimen current drug within 7 day prior administration GSK189075 ) . No restriction place use insulin , 1,25 dihydroxyvitamin D3 ( Rocaltrol ) , erythropoietin , calcium aluminumcontaining phosphate binder . Subjects whose current medication therapy agreement information provide Sections 9.1 , 9.2 , 9.3 protocol . Serum albumin less 2.5 g/dL . Hemoglobin le 8.5 g/dL . Additional Exclusion Criteria Subjects Normal Renal Function Any clinically relevant abnormality identify screen physical laboratory examination . Any abnormality outside normal reference range Screening may repeat must review GSK Medical Monitor prior enrollment subject study . Hemoglobin hematocrit reference range Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>renal insufficiency</keyword>
</DOC>